ZMAP 40-60% cure. SRPT 60 to 80% cure and lost funding while TKMR got it. SPRT has to successfully pass the monkey test KTMR passed at 100% cure. GSK only has a vaccine in a year and a half (maybe). J&J want in the game and is clueless. The weakness is the early players cashing in. The HEP news alone in the second half of 2014 should keep the share price here, The curing dangerous viruses like Ebola is a game changer.
This will validate the company’s technology and progress. Before Ebola, the play on this company was for it's hepatitis B results, which are due out soon enough. TKM-HBV is being developed as a multi-component RNAi therapeutic that targets multiple sites on the HBV genome. Because HBV is a viral infection of the liver, the TKM-HBV therapeutic will employ a liver-centric-LNP formulation that is more potent and has a broader therapeutic index than any LNP currently in clinical development. We anticipate completing the necessary preclinical work and expect to file an Investigational New Drug (IND) application in the second half of 2014. We plan to advance TKM-HBV into chronically infected HBV patients. The sudden, unexpected piece of good fortune will make the stock double. "We are carefully evaluating options for use of the Ebola drug within accepted clinical and regulatory protocols," Tekmira Chief Executive Mark Murray said.
hold on to those shares the news the last two days confirms TKMR is the 40 dollar stock. People are not stupid enough to fall for the ZMAPP fiasco. That's next to murder in my books.
You don't have a clue as what is going on. The brain dead half witted monkeys on ZMAPP is smarter. ZMAPP only had a 40 to 60% cure rate about the same as the disease. GSK is a vaccine. SPRD has a 60 to 80% cure and will take a long time to get the doses. TKMR is the only show in town with 100% cure and can ramp. You are seeing some profit takers on weakness only. It does not reflect the situation or companies future. The future is bright as all arsenals may be needed if this goes air born and mutates. It is very possible and ZMAPP was introduced by a third party purse organization. I will be glad to educate your #$%$.
unless Africa gets a placebo and we all feel good thinking we did all we could do. SIC
ZMAPP cure rate is 40 to 60% and doing more harm then good. The author did not do his DD as I found the cure rate in another article. You cant agree with the author as what good is a free drug that does nothing. This is sic.
thousands of viruses could move this higher then that. Its interesting how they are walking this down with ZMAPP useless, SPRD to far out and the number one up is only briefly mentioned. THE FDA holds the game changing card. I think it will be played soon. 100% cure rate ..............da
These bashers are about to burn. This is a play for them to escape from the obvious. They read the WHO report that stated ZMAPP tested their drugs at the same rate of survival without the drug. In other words ZMAPP is useless. SPRD tested theirs at 60 to 80% cured rate and a lot better results. THE ONE line about TKMR states they were working with the FDA for a approval and 100% primate cure and has to be the best choice.
Pre market is nothing but a scare. The fund managers do their DD. They have the same information as we do. I am in long. Holding and awaiting news. The DOD and WHO is not clueless.
don't fool yourself as it has a it's hepatitis B results coming out also. There are thousands of viruses and TKMR will be successful. Viruses mutate all the time. TKMR will be and is the lead drug with the DOD at this time by the contract money given. You are playing a sic game
ZMAPP is done for quite a while and the WHO knows it. They shot their arsenal and it will take a long time to produce more. So your laugh is in very poor taste. How many will die before they use our drug? Will they hold TKMR back? or use it. SPRD program is dead and will take time to pass the primate test TKMR passed at 100%. also SPRD only had a 60 to 80% cure rate. I hold SPRD also by the way.
These test are un tested on humans and SRPT drug must be given in 14 within being infected at a 60 to 80% cure rate on primates. TKMR had a 100% cure rate and got the DOD contract. I think we will be getting TKMR news.
They need to act fast. Viruses mutate all the time and some do question if it can spread by air. We could jump like ICPT did when TKMR is used. . ICPT is up 58% in one day . AUG ZMAPP supply is exhausted and takes a long time to make from Tabaco leaves. Sarepta Therapeutics says it has 24 doses and it will take up 2 months to supply 100 doses. It must pass primate testing. . It must be injected within 14 day of being infected — SRPT- AVI-7537 — they lost funding in 2012. The program was stopped as it had only a 60 to 80% cure rate. . TKMR has a 100% cure rate on primates and is rampable. TKMR got a 140 million DOD contract. GSK said they can have a vaccine in 2015. The vaccine in no cure. We are at a stand still tell they decide to use TKMR which could be soon. __________________________________________________________________________________________________________________ Food and Drug Administration action may enable the use of the company's TKM-Ebola drug for individuals infected with Ebola virus. The company said a Food and Drug Administration action may enable the use of the company's TKM-Ebola drug for individuals infected with Ebola virus. WHY ? It works- It cured primates 100% if given within a certain time frame. The DOD needs a whole arsenal of viral drug candidates. Many of the companies may prosper. Its like a war on the virus before it changes and spreads. Viruses (4,000 or more) and their mutations are tricky and many drugs are needed. ALL drugs from ALL companies have become important.
nice find--- - Corgenix Provides Update on Ebola Test Kit NIH Grant
Published: August 11, 2014
Corgenix and Viral Hemorrhagic Fever Consortium partners start work on Ebola rapid diagnostic test kit development, provide status update and project timeline
DENVER--(BUSINESS WIRE)--Aug. 11, 2014-- Ebola virus outbreaks tend to occur every few years and then go away rapidly. However, this year’s outbreak is the worst in recorded history, with the total number of deaths approaching 1,000.
Corgenix and the VHFC were recently awarded a three-year, $2.9 million National Institutes of Health grant to continue work on the development of an Ebola rapid diagnostic test kit. Corgenix and the consortium have already developed and CE marked the ReLASV® rapid diagnostic test for the Lassa fever virus. Catalyst and timing- Given the current Ebola outbreak in West Africa, the largest ever recorded, Simpson said it’s clear that point-of-care testing will be needed in the future for the rapid identification and treatment of viral hemorrhagic fevers, including Lassa, Ebola and Marburg. Corgenix Rapid Diagnostic Ebola Test Research Earns Divisional Best Abstract Award at AACC 2014 Meeting
Business Wire - Wed Jul 30, 8:15AM CDT
Corgenix Medical Corporation (OTCBB: CONX) has been recognized for outstanding research presented today at the American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Expo 2014 in Chicago. Corgenix earned the award for its poster abstract "Development of a Point-of-Care Diagnostic for Ebola and Sudan Virus Detection," presented at the conference by Corgenix Research Associate Abby Jones, M.S.
Corgenix Joins Strategic Partners, Presents Science at AACC Meeting and Clinical Lab Expo 2014
Business Wire - Tue Jul 22, 8:15AM CDT
Corgenix Medical Corporation (OTC BB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, will collaborate with strategic partners and also present several scientific abstracts at the American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Expo 2014 in Chicago.
Corgenix enters into technology transfer & product development agreement for Mellitussfor gestational diabetes test GCD59
M2 - Tue Jul 15, 8:29AM CDT
Diagnostic test kits company Corgenix Medical (Other OTC:CONX) on Monday launched a technology transfer and product development agreement with Mellitus in support of clinical research and product commercialisation.
Corgenix Signs Technology Transfer, Product Development Agreement with Mellitus LLC for Gestational Diabetes Test
Business Wire - Mon Jul 14, 8:15AM CDT
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, today announced a technology transfer and product development agreement with Mellitus LLC of Cambridge, Mass. Mellitus is a private company that is developing a novel in vitro diagnostic test with potential clinical utility for diabetes. The test is based on the measurement of Glycated CD59 (GCD59.)
Corgenix, Research Group Announce NIH Grant to Advance Work on Ebola Rapid Diagnostic Test Kit
Business Wire - Thu Jun 26, 8:15AM CDT
Corgenix Medical Corporation (OTC BB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, has been awarded a three-year, $2.9 million National Institutes of Health (NIH) grant to advance the development of an Ebola rapid diagnostic test kit. Collaborating with Corgenix on the program will be members of the Viral Hemorrhagic Fever Consortium (VHFC), a collaboration of academic and industry members headed by Tulane University and partially funded with support from the NIH.
Corgenix, Tulane and Viral Hemorrhagic Fever Consortium Publish Promising Results from Lassa Fever Trial
Business Wire - Tue Apr 01, 8:15AM CDT
A Corgenix Medical (OTCBB:CONX) rapid diagnostic test (RDT) for the dangerous Lassa fever virus has demonstrated the ability to quickly detect the virus, responsible for the deaths of thousands and infection of hundreds of thousands in West Africa each year. That's according to the results of the five-year trial Lassa Fever in Post-Conflict Sierra Leone published in the PLOS Neglected Tropical Diseases Journal.
Corgenix and Research Partners to Expand Ebola Virus Testing Capabilities in Sierra Leone
Business Wire - Thu Mar 27, 8:15AM CDT
An outbreak of the deadly Ebola virus in West Africa has prompted Corgenix Medical Corporation (OTCBB:CONX) to extend its existing viral hemorrhagic fever (VHF) rapid test development to include the Ebola virus. Corgenix has already developed and CE marked a rapid test for the Lassa fever virus, another member of the VHF group of viruses.
Corgenix Board of Directors Announces Exploration of Strategic Alternatives
Business Wire - Wed Mar 12, 8:15AM CDT
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, announced today that the Company's Board of Directors has decided to explore strategic alternatives to enhance value for shareholders. These alternatives could include, among others, possible joint ventures, strategic partnerships or alliances, a sale of the Company or other possible transactions.
Corgenix Medical Corporation posts higher net income of USD178,497 for Q2 fiscal 2014
M2 - Fri Feb 14, 3:06AM CST
Diagnostic test kits company Corgenix Medical Corporation (OTC BB:CONX) reported on Thursday its net income of USD178,497 for second quarter fiscal 2014.
Corgenix to exhibit AspirinWorks® Test, present abstracts, including “best abstract” for Ebola research and first-ever oral presentation… Catalyst- Study results are being presented by Corgenix Regulatory and Clinical Affairs Specialist Bethany Belote and will be published in the October issue of Clinical Chemistry. Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases (including the world’s only non-blood-based test for aspirin effect), bone and joint disorders and a line of unique detection products for viral hemorrhagic disease. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience in product submissions to the FDA and other worldwide regulatory authorities. Among its five scientific presentations, Corgenix has been awarded Best Annual Meeting Abstract for AACC 2014 in the Critical and Point of Care Testing Division for Infectious Disease poster B- Ebola is indigenous to Africa and is one of the deadliest viruses on the planet, with mortality rates of between 50 and 90 percent. Ebola infection is characterized by bleeding and coagulation abnormalities and can kill within 10 days to two weeks. Ebola and other viral hemorrhagic fevers are difficult to diagnose because many of the early signs and symptoms resemble those of other infectious diseases such as typhoid and malaria. Financials- “The third-quarter and nine-month results were in line with our expectations,” stated Corgenix President and Chief Executive Officer Douglass Simpson. “Year to date we are showing improved results year over year in terms of both revenues and income, indicating continued demand for our products and services. It has been a good year so far, as we improved operating profit margins in a challenging market as a result of our focus on providing value-added products for our customers, diligent expense control and margin improvement.”